Skip to main content

Table 1 Patient recruitment

From: Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F–Fluorodeoxyglucose (18F–FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study

Inclusion criteria

 1. Adults (>18 years) capable of providing informed consent with metastatic renal cell cancer

 2. Eastern cooperative oncology group (ECOG) performance status ≤ 2

Exclusion criteria

 1. Estimated prognosis < 12 weeks

 2. Contraindications to contrast enhanced CT, MRI or FDG/PET

 3. Women who are pregnant or lactating

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us